Dartmouth team develops prognostic test for E2F4 in ER+ BC

JohnSmith

http://medicalxpress.com/news/2015-01-team-prognostic-e2f4-breast-cancer.html

I thought this news was interesting for those whose Oncotype scores were in the middle and the benefit from chemo is uncertain.

Researchers at Dartmouth, led by Dr. Chao Cheng, have identified a gene signature in E2F4 that is predictive of estrogen receptor positive (ER+) breast cancer. The findings, published in Breast Cancer Research, define a new opportunity for personalizing medicine for women whose Oncotype DX assay results classify them as of "intermediate-risk for recurrence." (The article did not specify the score range, but I'd assume it would apply to those who Recurrence Score was between 18 and 31).

According to the article, after it's developed, it should be a simple clinical test to determine future risk.

If you're like me and enjoy emailing the researchers, here's a link to Dr. Cheng's genetics lab at Dartmouth Medical School.